Types of Lactic Acidosis
Classification Framework
Lactic acidosis is classified into two major types based on the presence or absence of tissue hypoxia: Type A results from inadequate tissue oxygen delivery due to hypoperfusion or hypoxia, while Type B occurs without tissue hypoxia due to metabolic disturbances, drug toxicity, or malignancy. 1, 2
Type A Lactic Acidosis (Tissue Hypoxia-Related)
Type A lactic acidosis develops when oxygen delivery to tissues is insufficient, forcing cells to rely on anaerobic metabolism and converting pyruvate to lactate to regenerate NAD+. 2
Primary Causes
Circulatory disorders including all forms of shock (hypovolemic, cardiogenic, distributive, obstructive), cardiac failure, and severe hypotension lead to inadequate tissue perfusion and oxygen delivery. 1, 2
Severe infections and sepsis cause tissue hypoperfusion through both decreased perfusion pressure and increased metabolic demands. 1, 2
Acute mesenteric ischemia produces lactic acidosis through intestinal hypoperfusion, with lactate >2 mmol/L indicating irreversible intestinal ischemia (Hazard Ratio: 4.1). 1, 2
Respiratory failure resulting in hypoxemia limits oxygen availability to tissues. 2
Severe anemia reduces oxygen-carrying capacity below the threshold needed to meet tissue demands. 2
Hemorrhagic shock and major trauma create oxygen debt through blood loss and impaired perfusion. 1
Distinguishing Features
Lactate-to-pyruvate ratio >25:1 indicates Type A lactic acidosis, reflecting true tissue hypoxia. 3
Clinical signs of hypoperfusion are typically present: cold extremities, altered mental status, oliguria (<0.5 mL/kg/hr), narrow pulse pressure, and hypotension. 1
Type B Lactic Acidosis (Non-Hypoxic)
Type B lactic acidosis occurs in the presence of normal oxygen delivery and results from metabolic dysfunction, drug effects, or pathologic cellular processes. 1, 4, 3
Type B1: Underlying Disease States
Malignancy-associated lactic acidosis occurs through the Warburg effect, where cancer cells preferentially use aerobic glycolysis even with adequate oxygen, producing excess lactate; this is most common with hematological malignancies (lymphoma, leukemia) and carries a poor prognosis. 1, 5, 6
Liver disease impairs lactate clearance because the liver is the major site of lactate removal through gluconeogenesis and oxidation. 1
Renal impairment reduces lactate clearance, with hyperlactatemia occurring in 30–65% of adults with chronic kidney disease. 1
Severe primary hypothyroidism may be accompanied by elevated lactate levels. 1
Type B2: Medication-Induced
Metformin causes lactic acidosis when clearance is impaired (eGFR <30 mL/min/1.73 m²) or when conditions causing anaerobic metabolism are present (sepsis, hypoxia, liver failure), with an incidence of 2–9 per 100,000 patients/year. 1
Nucleoside reverse transcriptase inhibitors (NRTIs), particularly stavudine and didanosine, cause mitochondrial toxicity by inhibiting DNA polymerase γ, with an incidence of approximately 1.3 cases per 1,000 person-years of NRTI exposure. 1
Beta-2 agonists (albuterol, long-acting beta agonists) cause lactate elevation through beta-adrenergic receptor stimulation in skeletal muscle, activating glycogenolysis and glycolysis independent of tissue perfusion. 7, 8, 4, 3
Epinephrine infusions increase lactate production through beta-2-adrenergic stimulation, creating elevated lactate without tissue hypoxia. 1, 7
Linezolid can precipitate Type B lactic acidosis through mitochondrial dysfunction. 1
Type B3: Inborn Errors of Metabolism
Organic acidemias including methylmalonic acidemia, propionic acidemia, and maple syrup urine disease disrupt normal oxidative metabolism. 1
Mitochondrial disorders such as MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) result from mtDNA mutations (80% carry the A3243G mutation) that impair oxidative phosphorylation. 1
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) presents with recurrent lactic acidosis, gastrointestinal dysmotility, leukoencephalopathy (96%), polyneuropathy (96%), and ophthalmoplegia (91%), caused by TYMP gene mutations. 1
Glycogen storage disease Type I produces chronic hyperlactatemia due to deficient glucose-6-phosphatase activity and impaired gluconeogenesis, presenting with fasting hypoglycemia, hepatomegaly, hypertriglyceridemia, and hyperuricemia. 9, 1
Thiamine (B1) deficiency affects pyruvate dehydrogenase function, preventing glucose utilization through aerobic metabolism pathways and causing Type B lactic acidosis. 1, 10, 11
Distinguishing Features
Lactate-to-pyruvate ratio <25:1 (typically 10–25) indicates Type B lactic acidosis, reflecting metabolic dysfunction rather than tissue hypoxia. 3
Hemodynamic stability is typically maintained, with normal blood pressure, adequate urine output, and absence of clinical hypoperfusion signs. 5
Central venous oxygen saturation (ScvO₂) is often >70% or even elevated, paradoxically indicating impaired cellular oxygen utilization rather than inadequate delivery. 9
Special Subtype: D-Lactic Acidosis
D-lactic acidosis occurs in patients with short bowel syndrome and preserved colon, where bacterial overgrowth produces D-lactate through fermentation of unabsorbed carbohydrates. 1
Standard lactate assays measure only L-lactate, so D-lactic acidosis requires specific testing and presents with neurological symptoms (confusion, ataxia) alongside metabolic acidosis. 1
Critical Diagnostic Distinction
The fundamental difference between Type A and Type B is the presence or absence of tissue hypoxia—Type A requires immediate restoration of tissue perfusion, while Type B requires identification and treatment of the underlying metabolic cause, making this distinction essential for appropriate management. 1, 2, 5, 4
Key Pitfalls to Avoid
Do not assume all lactic acidosis in critically ill patients is Type A—up to 23% of septic patients have lactate ≥2 mmol/L with ScvO₂ >70%, representing "cryptic shock" or Type B mechanisms. 1
Do not dismiss nonspecific gastrointestinal symptoms (nausea, vomiting, abdominal pain) in at-risk patients taking metformin or NRTIs, as these may precede severe Type B lactic acidosis by 1–6 weeks. 1
Do not overlook medication-induced causes—review all medications, particularly metformin, NRTIs, beta-agonists, and linezolid, when encountering unexplained hyperlactatemia. 1, 8, 4
Do not ignore persistent hyperlactatemia despite adequate resuscitation—this pattern suggests Type B lactic acidosis and warrants evaluation for malignancy (especially lymphoma), thiamine deficiency, or mitochondrial disorders. 1, 5, 10, 6, 11